Cancer chemoprevention through dietary flavonoids: what’s limiting?
Abstract Flavonoids are polyphenols that are found in numerous edible plant species. Data obtained from preclinical and clinical studies suggest that specific flavonoids are chemo-preventive and cytotoxic against various cancers via a multitude of mechanisms. However, the clinical use of flavonoids...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-06-01
|
Series: | Chinese Journal of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40880-017-0217-4 |
id |
doaj-19063cb1455c459b9d431c9d54999abc |
---|---|
record_format |
Article |
spelling |
doaj-19063cb1455c459b9d431c9d54999abc2020-11-25T01:21:23ZengBMCChinese Journal of Cancer1944-446X2017-06-0136111310.1186/s40880-017-0217-4Cancer chemoprevention through dietary flavonoids: what’s limiting?Haneen Amawi0Charles R. Ashby1Amit K. Tiwari2Department of Pharmacology and Systems Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of ToledoPharmaceutical Sciences, College of Pharmacy, St. John’s UniversityDepartment of Pharmacology and Systems Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of ToledoAbstract Flavonoids are polyphenols that are found in numerous edible plant species. Data obtained from preclinical and clinical studies suggest that specific flavonoids are chemo-preventive and cytotoxic against various cancers via a multitude of mechanisms. However, the clinical use of flavonoids is limited due to challenges associated with their effective use, including (1) the isolation and purification of flavonoids from their natural resources; (2) demonstration of the effects of flavonoids in reducing the risk of certain cancer, in tandem with the cost and time needed for epidemiological studies, and (3) numerous pharmacokinetic challenges (e.g., bioavailability, drug–drug interactions, and metabolic instability). Currently, numerous approaches are being used to surmount some of these challenges, thereby increasing the likelihood of flavonoids being used as chemo-preventive drugs in the clinic. In this review, we summarize the most important challenges and efforts that are being made to surmount these challenges.http://link.springer.com/article/10.1186/s40880-017-0217-4FlavonoidsChemopreventionSilybinSilymarinNatural product drug developmentPharmacokinetic challenges |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Haneen Amawi Charles R. Ashby Amit K. Tiwari |
spellingShingle |
Haneen Amawi Charles R. Ashby Amit K. Tiwari Cancer chemoprevention through dietary flavonoids: what’s limiting? Chinese Journal of Cancer Flavonoids Chemoprevention Silybin Silymarin Natural product drug development Pharmacokinetic challenges |
author_facet |
Haneen Amawi Charles R. Ashby Amit K. Tiwari |
author_sort |
Haneen Amawi |
title |
Cancer chemoprevention through dietary flavonoids: what’s limiting? |
title_short |
Cancer chemoprevention through dietary flavonoids: what’s limiting? |
title_full |
Cancer chemoprevention through dietary flavonoids: what’s limiting? |
title_fullStr |
Cancer chemoprevention through dietary flavonoids: what’s limiting? |
title_full_unstemmed |
Cancer chemoprevention through dietary flavonoids: what’s limiting? |
title_sort |
cancer chemoprevention through dietary flavonoids: what’s limiting? |
publisher |
BMC |
series |
Chinese Journal of Cancer |
issn |
1944-446X |
publishDate |
2017-06-01 |
description |
Abstract Flavonoids are polyphenols that are found in numerous edible plant species. Data obtained from preclinical and clinical studies suggest that specific flavonoids are chemo-preventive and cytotoxic against various cancers via a multitude of mechanisms. However, the clinical use of flavonoids is limited due to challenges associated with their effective use, including (1) the isolation and purification of flavonoids from their natural resources; (2) demonstration of the effects of flavonoids in reducing the risk of certain cancer, in tandem with the cost and time needed for epidemiological studies, and (3) numerous pharmacokinetic challenges (e.g., bioavailability, drug–drug interactions, and metabolic instability). Currently, numerous approaches are being used to surmount some of these challenges, thereby increasing the likelihood of flavonoids being used as chemo-preventive drugs in the clinic. In this review, we summarize the most important challenges and efforts that are being made to surmount these challenges. |
topic |
Flavonoids Chemoprevention Silybin Silymarin Natural product drug development Pharmacokinetic challenges |
url |
http://link.springer.com/article/10.1186/s40880-017-0217-4 |
work_keys_str_mv |
AT haneenamawi cancerchemopreventionthroughdietaryflavonoidswhatslimiting AT charlesrashby cancerchemopreventionthroughdietaryflavonoidswhatslimiting AT amitktiwari cancerchemopreventionthroughdietaryflavonoidswhatslimiting |
_version_ |
1725130594854109184 |